• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    EXL Announces Appointment of Andreas Fibig to Board of Directors

    1/12/23 4:01:00 PM ET
    $EXLS
    $IFF
    $NVO
    Real Estate
    Real Estate
    Major Chemicals
    Industrials
    Get the next $EXLS alert in real time by email

    NEW YORK, Jan. 12, 2023 (GLOBE NEWSWIRE) -- ExlService Holdings, Inc. (NASDAQ:EXLS), a leading global data analytics and digital operations and solutions company, today announced that Andreas Fibig, a seasoned global executive with a strong record of innovation across industries and geographies, has been appointed to EXL's Board of Directors as an independent director effective Jan. 10, 2023. Fibig will be a member of the Board's Audit and Nominating and Governance Committees.

    "Andreas is a distinguished global business leader with more than 25 years of international health care, pharmaceutical, and consumer industry experience," said Vikram S. Pandit, Chairman of the Board of EXL. "We look forward to the insights and contributions Andreas will bring to the Board and leadership team as the company executes on its growth strategy."

    EXL Vice Chairman and Chief Executive Officer Rohit Kapoor said, "We are delighted to welcome Andreas to our Board of Directors. His years of experience leading large global organizations will provide us with valuable insight and perspective as we rapidly scale EXL into the dominant global player in analytics and digital operations. Andreas also brings a unique combination of experience in international markets along with a deep understanding of U.S. business, which will benefit EXL as we continue our geographic expansion, particularly in Europe."

    "I'm truly excited to join the EXL Board at this stage in the company's journey," said Fibig. "EXL's transformation to a data-led analytics and digital operations company has resulted in remarkable growth and significant improvement in profitability. I look forward to working with the Board and management team to help the company continue its growth trajectory as well as create sustainable competitive advantage through its digital strategy. I am also honored to be part of an organization that focuses on sustainability as part of its enterprise strategy, and I'm excited to help further those efforts."

    Fibig spent 10 years with International Flavors & Fragrances (NYSE:IFF), an industry leader in food ingredients, beverage, scent, health care and biosciences, including seven years as Chairman and CEO. There, he established a record of driving strong growth as well as leading the company through significant transformation, including the integration of DuPont Nutrition & Biosciences following a merger. Prior to that, he served as president and chairman of the board of management for Bayer Health Care Pharmaceuticals, where he was the chief executive responsible for Bayer's global health care and pharmaceutical business. He currently serves on the board of Novo-Nordisk A/S (NYSE:NVO), where he is an independent director and member of the Research and Development Committee. He also serves as a director of Indigo Agriculture and EvodiaBio, which are private companies. He previously served on the board of Bunge Limited, a leading global agribusiness and food company.

    About EXL

    EXL (NASDAQ:EXLS) is a leading data analytics and digital operations and solutions company that partners with clients to improve business outcomes and unlock growth. By bringing together deep domain expertise with robust data, powerful analytics, cloud, artificial intelligence ("AI") and machine learning ("ML"), we create agile, scalable solutions and execute complex operations for the world's leading corporations in industries including insurance, healthcare, banking and financial services, media, and retail, among others. Focused on driving faster decision-making and transforming operating models, EXL was founded on the core values of innovation, collaboration, excellence, integrity and respect. Headquartered in New York, our team is over 43,100 strong, with more than 50 offices spanning six continents. For more information, visit www.exlservice.com.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains forward-looking statements. You should not place undue reliance on those statements because they are subject to numerous uncertainties and factors relating to EXL's operations and business environment, all of which are difficult to predict and many of which are beyond EXL's control. Forward-looking statements include information concerning EXL's possible or assumed future results of operations, including descriptions of its business strategy. These statements may include words such as "may," "will," "should," "believe," "expect," "anticipate," "intend," "plan," "estimate" or similar expressions. These statements are based on assumptions that we have made in light of management's experience in the industry as well as its perceptions of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. You should understand that these statements are not guarantees of performance or results. They involve known and unknown risks, uncertainties and assumptions. Although EXL believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect EXL's actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements. These factors, which include our ability to successfully close and integrate strategic acquisitions, our ability to respond to and manage public health crises, including the outbreak and continued effects of COVID-19 pandemic, are discussed in more detail in EXL's filings with the Securities and Exchange Commission, including EXL's Quarterly Report on Form 10-Q and Annual Report on Form 10-K. These risks could cause actual results to differ materially from those implied by forward-looking statements in this release. You should keep in mind that any forward-looking statement made herein, or elsewhere, speaks only as of the date on which it is made. New risks and uncertainties come up from time to time, and it is impossible to predict these events or how they may affect EXL. EXL has no obligation to update any forward-looking statements after the date hereof, except as required by federal securities laws.

    © 2023 ExlService Holdings, Inc. All rights reserved. For more information go to www.exlservice.com/legal-disclaimer

    Contacts

    Media 

    Keith Little

    Senior Manager, Media Relations

    +1 703-598-0980 

    [email protected]

    Investor Relations

    John Kristoff

    +1 212 209 4613

    [email protected]



    Primary Logo

    Get the next $EXLS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EXLS
    $IFF
    $NVO

    CompanyDatePrice TargetRatingAnalyst
    Novo Nordisk A/S
    $NVO
    10/27/2025Underperform
    Jefferies
    Novo Nordisk A/S
    $NVO
    10/1/2025Hold → Buy
    HSBC Securities
    Novo Nordisk A/S
    $NVO
    9/29/2025$47.00Equal-Weight → Underweight
    Morgan Stanley
    Novo Nordisk A/S
    $NVO
    9/17/2025Hold → Buy
    Berenberg
    Novo Nordisk A/S
    $NVO
    9/16/2025Neutral → Buy
    Rothschild & Co Redburn
    Novo Nordisk A/S
    $NVO
    9/9/2025Mkt Perform → Outperform
    Bernstein
    International Flavors & Fragrances Inc.
    $IFF
    9/8/2025Underperform → Peer Perform
    Wolfe Research
    Novo Nordisk A/S
    $NVO
    8/13/2025$54.00Underperform → Neutral
    BNP Paribas Exane
    More analyst ratings

    $EXLS
    $IFF
    $NVO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fribourg Paul J bought $1,001,183 worth of shares (15,450 units at $64.80) (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    8/8/25 6:49:19 PM ET
    $IFF
    Major Chemicals
    Industrials

    Chief Executive Officer Fyrwald J Erik bought $993,714 worth of shares (15,300 units at $64.95), increasing direct ownership by 25% to 77,370 units (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    8/7/25 6:59:38 PM ET
    $IFF
    Major Chemicals
    Industrials

    Director O'Byrne Kevin bought $342,240 worth of shares (4,500 units at $76.05), increasing direct ownership by 141% to 7,696 units (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    5/23/25 4:46:40 PM ET
    $IFF
    Major Chemicals
    Industrials

    $EXLS
    $IFF
    $NVO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 8, 2024 - FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight

    For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced calorie diet and increased physical activity. Cardiovascular disease is a gr

    3/8/24 2:00:18 PM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EXLS
    $IFF
    $NVO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Data and AI Leader EXL to host 'IdeaTank' innovation event at the Nasdaq MarketSite

    More than 11,000 pitch ideas submitted from EXL employees globally Shark Tank's Robert Herjavec to join EXL IdeaTank event NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- EXL (NASDAQ:EXLS), a global data and AI company, announced that it will hold its second annual IdeaTank event at the Nasdaq MarketSite on December 8, 2025. A celebration of EXL's innovation-at-speed culture and AI-native workforce, the event features new data and AI pitch ideas submitted from EXL's global employee base. Winning ideas receive funding and fast-track development resources to launch new capabilities and breakthrough client solutions. Now in its second year, the 2025 IdeaTank has received more than 11,000 submi

    11/25/25 2:26:35 PM ET
    $EXLS
    Real Estate

    Mativ Announces Appointment of Seasoned Executive to Its Board of Directors

    Deborah Borg Brings 25+ Years of Corporate Leadership to Global Manufacturing Leader Mativ Holdings, Inc. (NYSE:MATV) announced today the appointment of Deborah Borg to its Board of Directors, effective immediately. In her role on the Mativ Board of Directors, Borg will serve on the Company's Compensation Committee and Nominating & Governance Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251124104625/en/Deborah Borg, Mativ Board of Directors Borg is currently the Executive Vice President, Chief People & Culture Officer at International Flavors & Fragrances Inc. (NYSE:IFF), a global leader in food, beverage, health, b

    11/24/25 4:05:00 PM ET
    $IFF
    $MATV
    $SWM
    Major Chemicals
    Industrials
    Paper
    Basic Materials

    IFF Introduces Smart Dosing Robot to Transform Fragrance Production

    New technology delivers quicker, more precise creative sampling for IFF customers across Greater Asia. IFF (NYSE:IFF) — a global leader in flavors, fragrances, food ingredients, health and biosciences, has implemented the Colibri robot in its Chin Bee production facility. This advanced industrial dosing system can produce fragrance sample batches on demand in minutes, reimagining and expediting the fragrance development journey for local, regional and global customers in Greater Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251123090457/en/Photo credit: IFF - Colleagues at IFF Chin Bee with the site's new smart-dosing rob

    11/23/25 8:00:00 PM ET
    $IFF
    Major Chemicals
    Industrials

    $EXLS
    $IFF
    $NVO
    SEC Filings

    View All

    SEC Form 6-K filed by Novo Nordisk A/S

    6-K - NOVO NORDISK A S (0000353278) (Filer)

    11/25/25 8:19:20 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Novo Nordisk A/S

    6-K - NOVO NORDISK A S (0000353278) (Filer)

    11/24/25 7:23:52 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Novo Nordisk A/S

    6-K - NOVO NORDISK A S (0000353278) (Filer)

    11/17/25 3:35:39 PM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EXLS
    $IFF
    $NVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Vice President Kini Narasimha gifted 5,000 shares, decreasing direct ownership by 3% to 178,842 units (SEC Form 4)

    4 - ExlService Holdings, Inc. (0001297989) (Issuer)

    11/13/25 8:03:55 PM ET
    $EXLS
    Real Estate

    Director Icahn Brett was granted 33,000 shares (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    11/12/25 5:17:06 PM ET
    $IFF
    Major Chemicals
    Industrials

    Director O'Byrne Kevin was granted 8,750 shares, increasing direct ownership by 88% to 14,446 units (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    11/10/25 4:48:21 PM ET
    $IFF
    Major Chemicals
    Industrials

    $EXLS
    $IFF
    $NVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Novo Nordisk A/S

    Jefferies resumed coverage of Novo Nordisk A/S with a rating of Underperform

    10/27/25 8:47:58 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novo Nordisk A/S upgraded by HSBC Securities

    HSBC Securities upgraded Novo Nordisk A/S from Hold to Buy

    10/1/25 12:08:46 PM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novo Nordisk A/S downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Novo Nordisk A/S from Equal-Weight to Underweight and set a new price target of $47.00

    9/29/25 9:51:57 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EXLS
    $IFF
    $NVO
    Leadership Updates

    Live Leadership Updates

    View All

    Data and AI Leader EXL to host 'IdeaTank' innovation event at the Nasdaq MarketSite

    More than 11,000 pitch ideas submitted from EXL employees globally Shark Tank's Robert Herjavec to join EXL IdeaTank event NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- EXL (NASDAQ:EXLS), a global data and AI company, announced that it will hold its second annual IdeaTank event at the Nasdaq MarketSite on December 8, 2025. A celebration of EXL's innovation-at-speed culture and AI-native workforce, the event features new data and AI pitch ideas submitted from EXL's global employee base. Winning ideas receive funding and fast-track development resources to launch new capabilities and breakthrough client solutions. Now in its second year, the 2025 IdeaTank has received more than 11,000 submi

    11/25/25 2:26:35 PM ET
    $EXLS
    Real Estate

    Mativ Announces Appointment of Seasoned Executive to Its Board of Directors

    Deborah Borg Brings 25+ Years of Corporate Leadership to Global Manufacturing Leader Mativ Holdings, Inc. (NYSE:MATV) announced today the appointment of Deborah Borg to its Board of Directors, effective immediately. In her role on the Mativ Board of Directors, Borg will serve on the Company's Compensation Committee and Nominating & Governance Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251124104625/en/Deborah Borg, Mativ Board of Directors Borg is currently the Executive Vice President, Chief People & Culture Officer at International Flavors & Fragrances Inc. (NYSE:IFF), a global leader in food, beverage, health, b

    11/24/25 4:05:00 PM ET
    $IFF
    $MATV
    $SWM
    Major Chemicals
    Industrials
    Paper
    Basic Materials

    IFF Announces Appointment of Brett Icahn and Richard Mulligan to Board of Directors

    IFF (NYSE:IFF)—a global leader in flavors, fragrances, food ingredients, health and biosciences—today announced the appointment of Brett Icahn and Richard Mulligan, Ph.D., to its board of directors, effective Oct. 20. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022380951/en/Brett Icahn (Photo: IFF) These appointments follow the company's previously disclosed cooperation agreement with Icahn Capital LP and its affiliates. Icahn serves as the Icahn designee to the IFF board, replacing Vincent Intrieri, and Mulligan joined as the mutually agreed independent director, replacing Margarita Paláu-Hernández. Intrieri and Paláu-Her

    10/22/25 4:15:00 PM ET
    $IFF
    Major Chemicals
    Industrials

    $EXLS
    $IFF
    $NVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ExlService Holdings Inc.

    SC 13G/A - ExlService Holdings, Inc. (0001297989) (Subject)

    11/12/24 9:55:17 AM ET
    $EXLS
    Real Estate

    SEC Form SC 13G/A filed by International Flavors & Fragrances Inc. (Amendment)

    SC 13G/A - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Subject)

    3/8/24 4:44:49 PM ET
    $IFF
    Major Chemicals
    Industrials

    SEC Form SC 13G/A filed by International Flavors & Fragrances Inc. (Amendment)

    SC 13G/A - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Subject)

    2/13/24 5:07:58 PM ET
    $IFF
    Major Chemicals
    Industrials

    $EXLS
    $IFF
    $NVO
    Financials

    Live finance-specific insights

    View All

    /C O R R E C T I O N -- Metsera, Inc./

    In the news release, Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal "Superior", issued 04-Nov-2025 by Metsera, Inc. over PR Newswire, we are advised by the company that the second paragraph, third sentence, should begin "Shortly thereafter,..." rather than "On the same day,...", and the third paragraph, first sentence, should read "...representing up to $24.00 per share in cash (up from $21.25)..." rather than "...representing up to $24.00 per share in cash (up from $22.50)..." as originally issued inadvertently. The complete, corrected release follows: Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Ame

    11/4/25 9:09:00 AM ET
    $MTSR
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal "Superior"

    Novo Nordisk Amended Proposal Values Metsera at up to $86.20 per Share, a Total of Approximately $10.0 Billion Superior to Revised Pfizer Proposal that Valued Metsera at up to $70.00 per Share, a Total of Approximately $8.1 Billion Pursuant to Pfizer Merger Agreement, Metsera and Pfizer May Negotiate Potential Adjustments for Two Business Days Pfizer Merger Agreement Remains in Effect; No Action Required by Metsera Shareholders NEW YORK, Nov. 4, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ:MTSR) ("Metsera") today announced that its Board of Directors had determined, after consultation with its outside counsel and financial advisors, that a revised proposal that Metsera received from Novo Nord

    11/4/25 9:09:00 AM ET
    $MTSR
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IFF Declares Dividend for Fourth Quarter 2025

    IFF (NYSE:IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on January 9, 2026 to shareholders of record as of December 19, 2025. Welcome to IFF At IFF (NYSE:IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2025 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All R

    10/30/25 4:15:00 PM ET
    $IFF
    Major Chemicals
    Industrials